Anthony Rothschild to Mental Disorders
This is a "connection" page, showing publications Anthony Rothschild has written about Mental Disorders.
Connection Strength
1.123
-
Rothschild AJ. Advancing the Development of New Medications to Treat Psychiatric Illness. J Clin Psychopharmacol. 2022 Nov-Dec 01; 42(6):517.
Score: 0.482
-
Rothschild AJ. The Pitfalls of Psychotropic Polypharmacy. J Clin Psychopharmacol. 2021 May-Jun 01; 41(3):227-232.
Score: 0.436
-
Rothschild AJ, Shindul-Rothschild JA, Viguera A, Murray M, Brewster S. Comparison of the frequency of behavioral disinhibition on alprazolam, clonazepam, or no benzodiazepine in hospitalized psychiatric patients. J Clin Psychopharmacol. 2000 Feb; 20(1):7-11.
Score: 0.100
-
?stergaard SD, Fava M, Rothschild AJ, Deligiannidis KM. The implications of the National Institute of Mental Health Research Domain Criteria for researchers and clinicians. Acta Psychiatr Scand. 2014 Dec; 130(6):409-14.
Score: 0.069
-
Shindul-Rothschild J, Rothschild AJ. Benzodiazepine response. Am J Nurs. 2001 Nov; 101(11):13-4.
Score: 0.028
-
Rothschild AJ, Langlais PJ, Schatzberg AF, Walsh FX, Cole JO, Bird ED. Dexamethasone increases plasma free dopamine in man. J Psychiatr Res. 1984; 18(3):217-23.
Score: 0.008